CN113677347A - Tyk2假激酶配体 - Google Patents

Tyk2假激酶配体 Download PDF

Info

Publication number
CN113677347A
CN113677347A CN202080026979.3A CN202080026979A CN113677347A CN 113677347 A CN113677347 A CN 113677347A CN 202080026979 A CN202080026979 A CN 202080026979A CN 113677347 A CN113677347 A CN 113677347A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080026979.3A
Other languages
English (en)
Chinese (zh)
Inventor
拉朱·莫汉
约翰·努斯
詹森·哈里斯
袁沈东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Winterx Biosciences
Original Assignee
Winterx Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winterx Biosciences filed Critical Winterx Biosciences
Publication of CN113677347A publication Critical patent/CN113677347A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080026979.3A 2019-02-07 2020-02-07 Tyk2假激酶配体 Pending CN113677347A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802642P 2019-02-07 2019-02-07
US62/802,642 2019-02-07
PCT/US2020/017314 WO2020163778A1 (en) 2019-02-07 2020-02-07 Tyk2 pseudokinase ligands

Publications (1)

Publication Number Publication Date
CN113677347A true CN113677347A (zh) 2021-11-19

Family

ID=71947508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080026979.3A Pending CN113677347A (zh) 2019-02-07 2020-02-07 Tyk2假激酶配体

Country Status (12)

Country Link
US (1) US20220135567A1 (https=)
EP (1) EP3920931A4 (https=)
JP (1) JP2022519696A (https=)
KR (1) KR20210124409A (https=)
CN (1) CN113677347A (https=)
AU (1) AU2020218267A1 (https=)
BR (1) BR112021015616A2 (https=)
CA (1) CA3129438A1 (https=)
IL (1) IL285429A (https=)
MX (1) MX2021009555A (https=)
SG (1) SG11202108619SA (https=)
WO (1) WO2020163778A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061180A1 (zh) * 2023-09-22 2025-03-27 杭州多域生物技术有限公司 含氮并环类化合物、其药物组合物及其应用
WO2025168035A1 (zh) * 2024-02-07 2025-08-14 合肥羿科医药有限公司 杂环类化合物、其药物组合物及其应用
WO2025214467A1 (zh) * 2024-04-12 2025-10-16 江苏恒瑞医药股份有限公司 氨基取代的杂芳环类化合物、其制备方法及其在医药上的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019364336B2 (en) 2018-10-22 2023-11-16 Alumis Inc. TYK2 inhibitors and uses thereof
AU2020247990A1 (en) 2019-03-26 2021-11-11 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
KR102938141B1 (ko) 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드
AU2021345181A1 (en) * 2020-09-16 2023-05-04 Alumis Inc Tyk2 inhibitors and uses thereof
CN117043164A (zh) * 2021-01-19 2023-11-10 安锐生物医药科技(广州)有限公司 咪唑并哒嗪或吡唑并嘧啶化合物和组合物
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用
WO2025165746A1 (en) * 2024-01-30 2025-08-07 Ennovathera, Inc. Certain chemical entities, compositions, and methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189632A1 (en) * 2003-02-28 2006-08-24 Kenichiro Kataoka Pyrazolo[1,5-A] pyrimidine derivatives
CN108368116A (zh) * 2015-11-23 2018-08-03 豪夫迈·罗氏有限公司 Janus激酶抑制剂、其组合物及用途
US20180258086A1 (en) * 2017-03-08 2018-09-13 Nimbus Lakshmi, Inc. Tyk2 inhibitors, uses, and methods for production thereof
WO2018215390A1 (en) * 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
US20190031664A1 (en) * 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102271515B (zh) * 2008-10-31 2014-07-02 健泰科生物技术公司 吡唑并嘧啶jak抑制剂化合物和方法
US10479793B2 (en) * 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
JP7179161B2 (ja) * 2018-09-10 2022-11-28 イーライ リリー アンド カンパニー 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体
JP7619951B2 (ja) * 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
TWI800696B (zh) * 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
KR102938141B1 (ko) * 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189632A1 (en) * 2003-02-28 2006-08-24 Kenichiro Kataoka Pyrazolo[1,5-A] pyrimidine derivatives
CN108368116A (zh) * 2015-11-23 2018-08-03 豪夫迈·罗氏有限公司 Janus激酶抑制剂、其组合物及用途
US20180258086A1 (en) * 2017-03-08 2018-09-13 Nimbus Lakshmi, Inc. Tyk2 inhibitors, uses, and methods for production thereof
WO2018215390A1 (en) * 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
US20190031664A1 (en) * 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061180A1 (zh) * 2023-09-22 2025-03-27 杭州多域生物技术有限公司 含氮并环类化合物、其药物组合物及其应用
WO2025168035A1 (zh) * 2024-02-07 2025-08-14 合肥羿科医药有限公司 杂环类化合物、其药物组合物及其应用
WO2025214467A1 (zh) * 2024-04-12 2025-10-16 江苏恒瑞医药股份有限公司 氨基取代的杂芳环类化合物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
EP3920931A1 (en) 2021-12-15
US20220135567A1 (en) 2022-05-05
SG11202108619SA (en) 2021-09-29
CA3129438A1 (en) 2020-08-13
BR112021015616A2 (pt) 2021-11-09
MX2021009555A (es) 2021-10-13
AU2020218267A1 (en) 2021-09-30
EP3920931A4 (en) 2022-08-10
IL285429A (en) 2021-09-30
JP2022519696A (ja) 2022-03-24
KR20210124409A (ko) 2021-10-14
WO2020163778A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
CN113677347A (zh) Tyk2假激酶配体
CN113874021B (zh) Tyk2假激酶配体
JP7635228B2 (ja) Ｔｙｋ２偽キナーゼリガンド
CN114269734B (zh) Jak抑制剂
CN114555569A (zh) Nlrp3调节剂
CN115003300A (zh) Jak抑制剂
EP4431151A1 (en) Anti-sars-cov-2 drug
HK40064378A (en) Tyk2 pseudokinase ligands
CN115038436A (zh) Jak抑制剂
HK40080028A (en) Tyk2 pseudokinase ligands
HK40080624A (en) Jak inhibitors
HK40072097A (en) Jak inhibitors
HK40066192A (zh) Tyk2假激酶配体
HK40066192B (zh) Tyk2假激酶配体
HK40080028B (zh) Tyk2假激酶配体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064378

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211119

WD01 Invention patent application deemed withdrawn after publication